Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group has appointed independent non-executive director Ms. Xia Lian as a member of its nomination committee, effective 31 December 2025, expanding the committee to four members. The updated composition, led by chairman Professor Lo Yuk Lam and including Mr. Zhang Hua Qiao, Mr. Choy Sze Chung Jojo and Ms. Xia, underscores the company’s emphasis on strengthened corporate governance and oversight of board appointments as it continues to operate in a highly regulated and competitive pharmaceutical market.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd., incorporated in Bermuda and listed in Hong Kong, operates in the pharmaceutical industry, focusing on the research, development and commercialization of medicines. The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard corporate governance structure for a major listed pharmaceutical group.
Average Trading Volume: 22,731,099
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.92B
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.